HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors

NCT06822998 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: HF50

Sponsor

HighField Biopharmaceuticals Corporation